Compare EUDA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EUDA | MREO |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.8M | 50.3M |
| IPO Year | 2021 | 2017 |
| Metric | EUDA | MREO |
|---|---|---|
| Price | $16.96 | $0.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $55.00 | $1.50 |
| AVG Volume (30 Days) | 24.4K | ★ 1.6M |
| Earning Date | 12-19-2023 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $134.73 | $5,184.20 |
| Revenue Next Year | $195.03 | $55.51 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.20 |
| 52 Week High | $25.70 | $2.37 |
| Indicator | EUDA | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 66.87 |
| Support Level | $12.39 | $0.31 |
| Resistance Level | $18.90 | $0.35 |
| Average True Range (ATR) | 1.65 | 0.02 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 68.83 | 82.55 |
EUDA Health Holdings Ltd is a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. It offers inventive, accessible, and science-based health solutions to support the shift in regional healthcare from reactive medical treatment to proactive, longevity-focused care. The group also runs a Singapore-based property management business. It operates in two reportable segments: property management services and holistic wellness consumer products and services. Key revenue is generated from property management services that include management and security services for properties such as condominiums, residential apartments, business office buildings, and shopping malls.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).